Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
yahoo.com
news
2022-06-03 12:00:00

Viridian Therapeutics, Inc

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the 'Company' or 'Viridian'), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that a majority of the independent directors serving on the Company's Board of Directors approved the grant of stock options to purchase, an aggregate of 266,000 shares of the Company's common stock, to five new employees (the 'Inducement Grants') on June 1, 2022 (the 'Grant Date').
